Lifeward Ltd., a medical device company, designs, develops, and commercializes technologies that enable mobility and wellness in rehabilitation and daily life for individuals with physical and neurological conditions in …
Industry Peers
Medical Devices| Headline | Source | Time |
|---|---|---|
Older | ||
 Lifeward (LFWD) Reports Q2 Loss, Misses Revenue Estimates Lifeward (LFWD) delivered earnings and revenue surprises of +2.01% and -10.74%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock? | ||
 Ovid Therapeutics (OVID) Reports Q2 Loss, Beats Revenue Estimates Ovid Therapeutics (OVID) delivered earnings and revenue surprises of +20.00% and +388.67%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock? | ||
 Natera (NTRA) Reports Q2 Loss, Beats Revenue Estimates Natera (NTRA) delivered earnings and revenue surprises of 0.00% and +14.23%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock? | ||
 How The Lifeward (LFWD) Story Is Shifting With New Price Targets And Valuation Assumptions Lifeward’s analyst price target has shifted to US$10, prompting a closer look at what is driving this new reference point for the stock. Analysts link the change to updates in their fair value frameworks, which now align the US$10 target with revised assumptions around the company’s future financial profile. As you read on, you will see how this evolving narrative might shape your view of where Lifeward sits today and what to watch next. Analyst Price Targets don't always capture the full... | ||
Lifeward Ltd (LFWD) Q1 2026 Earnings Call Highlights: Navigating Challenges and Seizing Growth ... Lifeward Ltd (LFWD) reports a revenue dip amid supply chain issues but strengthens its position with strategic acquisitions and financing. | ||
 Lifeward (LFWD) Q1 2026 Earnings Transcript William Grant: Thank you, Almog, and thank you for everybody for joining us today. The first quarter of 2026 marked an important strategic milestone for Lifeward as we successfully completed the acquisition of Oratech. | ||
 Lifeward Ltd. Q1 2026 Earnings Call Summary Moby summary of Lifeward Ltd.'s Q1 2026 earnings call | ||
 Lifeward (LFWD) Reports Q1 Loss, Lags Revenue Estimates Lifeward (LFWD) delivered earnings and revenue surprises of -1,870.59% and -35.69%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock? | ||
 Keros Therapeutics, Inc. (KROS) Reports Q1 Loss, Misses Revenue Estimates Keros Therapeutics (KROS) delivered earnings and revenue surprises of -31.52% and -93.01%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock? | ||
 CryoPort, Inc. (CYRX) Reports Q1 Loss, Tops Revenue Estimates CryoPort (CYRX) delivered earnings and revenue surprises of -15.00% and +6.41%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock? | ||